COVID-19 Aşı Dozlarının Günlük Vaka, Ölüm Ve İyileşmeler Üzerindeki Etkisinin İncelenmesi: Türk Kamu Verilerinin İstatistiksel Analizi

Year 2024, Volume: 8 Issue: 3, 348 - 354, 17.12.2024

Ebru Uğraş , Erhan Şimşek

https://doi.org/10.46332/aemj.1425103

Abstract

Amaç: COVID-19 salgını tüm dünyayı etkilemiştir. Bu makale, Türkiye'de günlük Kovid-19 vakaları, ölüm ve iyileşmeler ile günlük COVID-19 aşıları arasındaki ilişkiyi ve aşı çalışmalarının etkinliğini araştırmayı amaçlamaktadır.

Araçlar ve Yöntem: Türkiye Cumhuriyeti Sağlık Bakanlığı verilerine dayanarak aşı dozları ile COVID-19 vakaları, ölüm sayısı ve iyileşen sayısı arasındaki ilişkinin araştırılması amaçlandı. Çalışmada, aşının ilk dozunun uygulandığı 13 Ocak 2021 ile günlük verilerin mevcut olduğu son tarih olan 31 Mayıs 2022 arasındaki dönem incelendi. Veriler Türkiye COVID-19 Pandemi İzleme Ekranı (TURCOVID19) platformundan elde edilmiştir. Toplam 504 günlük veriler analiz edildi.

Bulgular: Günlük ilk doz aşı sayısı 1.458.245, 2. doz aşı sayısı ise 912.226 olup, 1. ve 2. doz aşı sayısında yüksek değerler ortaya çıkmaktadır. Aşılama oranlarının yüksek olduğu dönemlerde günlük ölüm sayılarında azalma ve günlük iyileşme oranında artma görülmüştür. İyileşen vaka sayısı aşının 3. ve 4. dozlarının uygulanmasından sonra en yüksek seviyeye çıkmıştır.İki doz aşı aldıktan sonra enfekte olan kişi sayısının aşılanmayan enfekte kişi sayısına kıyasla önemli ölçüde azaldığı görülmüştür.

Sonuç: Dünya çapında ve Türkiye'de yapılan çeşitli çalışmalardan elde edilen sonuçlar, COVID-19 aşılarının hastalık yükünü azaltmadaki etkinliğini tutarlı bir şekilde ortaya koymaktadır.

Keywords

aşı, COVID-19, Türkiye, ölüm oranı

Analysis the Impact of COVID-19 Vaccine Doses on Daily Cases, Deaths, and Recoveries: A Statistical Analysis of Turkish Public Data

Abstract

Purpose: The COVID-19 epidemic has affected the entire world. This article aims to investigate the relationship between daily COVID-19 cases, deaths and recoveries, and daily COVID-19 vaccines in Turkey, and the effectiveness of vaccine studies.

Materials and Methods: Based on the data from the Ministry of Health of the Republic of Turkey, this study aims to investigate the relationship between vaccine doses and COVID-19 cases, deaths, and recoveries. The analysis covers the period from January 13, 2021, when the first dose of the vaccine was administered, to May 31, 2022, the most recent date for which daily data is available. The data were obtained from the Turkey COVID-19 Pandemic Monitoring Screen (TURCOVID19) platform, with a total of 504 days of data being analyzed.

Results: The daily number of first-dose vaccinations was 1,458,245, and the daily number of second-dose vaccinations was 912,226, with high values observed for both the first and second doses. During periods of high vaccination rates, a decrease in daily death counts and an increase in daily recovery rates were observed. The number of recovered cases reached its peak after the administration of the third and fourth doses of the vaccine. It was also observed that the number of individuals infected after receiving two doses of the vaccine was significantly lower compared to the number of infected individuals who were unvaccinated.

Conclusion: The results obtained from various studies conducted worldwide and in Turkey consistently demonstrate the effectiveness of COVID-19 vaccines in reducing the disease burden.

Keywords

COVID-19, death rate, Türkiye, vaccine

Ethical Statement

Since no data belonging to the living creature was used in our study and publicly available data were analyzed, it is not within the scope of articles that require ethics committee approval. (TÜBİTAK ULAKBİM. TR Index Ethical Principles Flowchart, Access address: https://trdizin.gov.tr/wp-content/uploads/2022/04/TRDizin_etik_ilkeleri_akis_semasi.pdf )

References

• 1. Tasli̇dere B, Sönmez E, Özdemi̇r S. Evaluation of patients admitted to the emergency department after Coronavac (Sinovac) vaccination? J Exp Clin Med. 2023;40(1):80-84.
• 2. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.
• 3. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020;383(18):1757-1766.
• 4. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-848.
• 5. World Health Organization (WHO). Diagnostic Testing for SARS-CoV-2: Interim Guidance. 2020 https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2/ Accessed date 18 June, 2023.
• 6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615.
• 7. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111.
• 8. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-2201.
• 9. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416.
• 10. Keech C, Albert G, Cho I, et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320-2332.
• 11. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27(9):1614-1621.
• 12. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412-1423.
• 13. Lopez Bernal J, Andrews N, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585-594.
• 14. Tenforde MW. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):674-679.
• 15. Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med. 2021;27(12):2108-2110.
• 16. Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. BMJ.2021;372(1065):n1065.
• 17. Uçar A, Arslan Ş, Manap H, et al. An Interactive and Real-Time Web Application for Monitoring the Covid-19 Pandemic in Turkey: TURCOVID19 Anatol Clin J Med Sci. 2020;(25):154-155.
• 18. Bernal JL, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373(1088), n1088.
• 19. TURCOVID19. https://turcovid19.com/. Accessed date18 July, 2023.
• 20. T.R. Ministry of Health COVID-19 Information Platform. T.R. Ministry of Health. General Coronavirus Table. https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html. Access date: 18 June, 2023.
• 21. Kline RB. Principles and Practice of Structural Equation Modeling. Guilford Publications; 2023:514.
• 22. Aminu IM, Shariff MNM. Strategic orientation, access to finance, business environment and SMEs performance in Nigeria: Data screening and preliminary analysis. Eur J Bus Manag. 2014;6(35):124-132.
• 23. TÜBİTAK ULAKBİM. TR Index Ethical Principles Flow Chart . https://trdizin.gov.tr/en/guide/ TR Dizin Accessed date 25 july 2023.
• 24. Uzun O, Akpolat T, Varol A, et al. COVID-19:Vaccination vs. hospitalization 2022;50(3):747-752.
• 25. Chen X, Huang H, Ju J, Sun R, Zhang J. Impact of vaccination on the COVID-19 pandemic in U.S. states. Sci Rep. 2022;12(1):1554.
• 26. Akova M, Unal S. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomized controlled trial. 2021;3.